In silico design of Mycobacterium tuberculosis epitope ensemble vaccines Preksha Shah 1 , Jaymisha Mistry 1 , Pedro A Reche 2 , Derek Gatherer 3 , & Darren R Flower 1,* 1 School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, United Kingdom, B4 7ET. 2 Immunomedicine Group, Facultad de Medicina, Departamento de Microbiologia I, Universidad Complutense de Madrid, Madrid, Spain. 3 Division of Biomedical & Life Sciences, Faculty of Health & Medicine, Lancaster University, Lancaster LA1 4YW, UK. * Corresponding author [email protected]44 121 204 5182
27
Embed
In silico design of Mycobacterium tuberculosis epitope ... · Effective T cell responses are essential for . M. tuberculosis. elimination The slow growth rate of . M. tuberculosis
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
In silico design of
Mycobacterium tuberculosis
epitope ensemble vaccines
Preksha Shah 1, Jaymisha Mistry 1,
Pedro A Reche 2,
Derek Gatherer 3,
& Darren R Flower 1,*
1 School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, United
Kingdom, B4 7ET.
2 Immunomedicine Group, Facultad de Medicina, Departamento de Microbiologia I,
Universidad Complutense de Madrid, Madrid, Spain.
3 Division of Biomedical & Life Sciences, Faculty of Health & Medicine, Lancaster University,
MLLAVTVSL, QSSFYSDW and KMRCGAPRY; indicate that our putative TB vaccines need both MHC I
and II epitopes to offer a broad population coverage. In vitro and in vivo testing of our ensemble
vaccine for protective immune responses and efficacy against Mycobacterium tuberculosis. This and
other work (22-24) indicates our evolving immunoinformatics design strategy, based on the rigorous
selection of pre-validated epitopes, is suitable for developing epitope ensemble vaccines across the
spectrum of key pathogens for human health.
Conflicts of Interest
There are no conflicts to declare
Acknowledgements
Funding: This research was supported by Aston University. PAR is supported by grants
BIO2014:54164-R and by Inmunotek S.L.
REFERENCES
1. WHO. Tuberculosis fact sheet, [online]. http://www.who.int/mediacentre/factsheets/fs104/en/ (accessed: 15th March 17)2017. 2. Migliori GB, Dheda K, Centis R, Mwaba P, Bates M, O'Grady J, et al. Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. Trop Med Int Health. 2010;15(9):1052-66. 3. Heemskerk D, Caws M, Marais B, Farrar J. Tuberculosis in Adults and Children. Wellcome Trust–Funded Monographs and Book Chapters. London2015. 4. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998;393(6685):537-44. 5. Mendez-Samperio P. Global Efforts in the Development of Vaccines for Tuberculosis: Requirements for Improved Vaccines Against Mycobacterium tuberculosis. Scandinavian Journal of Immunology. 2016;84(4):204-10. 6. Mendez-Samperio P. Research progress in the field of immunotherapeutic vaccination in human TB and the way ahead. Immunotherapy. 2016;8(9):987-9. 7. Zenteno-Cuevas R. Successes and failures in human tuberculosis vaccine development. Expert Opin Biol Ther. 2017:1-11. 8. Raviglione M, Sulis G. Tuberculosis 2015: Burden, Challenges and Strategy for Control and Elimination. Infect Dis Rep. 2016;8(2):6570. 9. Franco-Paredes C, Rouphael N, del Rio C, Santos-Preciado JI. Vaccination strategies to prevent tuberculosis in the new millennium: from BCG to new vaccine candidates. Int J Infect Dis. 2006;10(2):93-102. 10. Bali P, Tousif S, Das G, Van Kaer L. Strategies to improve BCG vaccine efficacy. Immunotherapy. 2015;7(9):945-8. 11. Romano M, Huygen K. An update on vaccines for tuberculosis - there is more to it than just waning of BCG efficacy with time. Expert Opin Biol Ther. 2012;12(12):1601-10. 12. Detmer A, Glenting J. Live bacterial vaccines--a review and identification of potential hazards. Microb Cell Fact. 2006;5:23. 13. Evans TG, Schrager L, Thole J. Status of vaccine research and development of vaccines for tuberculosis. Vaccine. 2016;34(26):2911-4. 14. Eccles SR, Mehta R. Disseminated BCG disease: A case report. Respiratory Medicine CME. 2011;4(3):112-3. 15. Wilkie ME, McShane H. TB vaccine development: where are we and why is it so difficult? Thorax. 2015;70(3):299-301. 16. Hoft DF, Blazevic A, Selimovic A, Turan A, Tennant J, Abate G, et al. Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naive Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial. EBioMedicine. 2016;7:278-86. 17. Gillard P, Yang PC, Danilovits M, Su WJ, Cheng SL, Pehme L, et al. Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study. Tuberculosis (Edinb). 2016;100:118-27. 18. Ndiaye BP, Thienemann F, Ota M, Landry BS, Camara M, Dieye S, et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2015;3(3):190-200. 19. Kagina BM, Tameris MD, Geldenhuys H, Hatherill M, Abel B, Hussey GD, et al. The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses. Vaccine. 2014;32(45):5908-17. 20. Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK. Peptide Vaccine: Progress and Challenges. Vaccines (Basel). 2014;2(3):515-36. 21. Slingluff CL, Jr. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J. 2011;17(5):343-50.
22. Molero-Abraham M, Lafuente EM, Flower DR, Reche PA. Selection of conserved epitopes from hepatitis C virus for pan-populational stimulation of T-cell responses. Clin Dev Immunol. 2013;2013:601943. 23. Sheikh QM, Gatherer D, Reche PA, Flower DR. Towards the knowledge-based design of universal influenza epitope ensemble vaccines. Bioinformatics. 2016;32(21):3233-9. 24. Damfo S, Reche P, Gatherer D, Flower D. In silico design of knowledge-based Plasmodium falciparum epitope ensemble vaccines. Journal of Molecular Graphics and Modelling. 2017:in press. 25. Peters B, Sidney J, Bourne P, Bui HH, Buus S, Doh G, et al. The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol. 2005;3(3):e91. 26. Peters B, Sidney J, Bourne P, Bui HH, Buus S, Doh G, et al. The design and implementation of the immune epitope database and analysis resource. Immunogenetics. 2005;57(5):326-36. 27. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997;25(17):3389-402. 28. Papadopoulos JS, Agarwala R. COBALT: constraint-based alignment tool for multiple protein sequences. Bioinformatics. 2007;23(9):1073-9. 29. Garcia-Boronat M, Diez-Rivero CM, Reinherz EL, Reche PA. PVS: a web server for protein sequence variability analysis tuned to facilitate conserved epitope discovery. Nucleic Acids Res. 2008;36(Web Server issue):W35-41. 30. Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A. 2013;110(22):E2046-53. 31. Greenbaum J, Sidney J, Chung J, Brander C, Peters B, Sette A. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics. 2011;63(6):325-35. 32. Kaufmann SH, McElrath MJ, Lewis DJ, Del Giudice G. Challenges and responses in human vaccine development. Curr Opin Immunol. 2014;28:18-26. 33. Amir A, Rana K, Arya A, Kapoor N, Kumar H, Siddiqui MA. Mycobacterium tuberculosis H37Rv: In Silico Drug Targets Identification by Metabolic Pathways Analysis. Int J Evol Biol. 2014;2014:284170. 34. Davila J, Zhang L, Marrs CF, Durmaz R, Yang Z. Assessment of the genetic diversity of Mycobacterium tuberculosis esxA, esxH, and fbpB genes among clinical isolates and its implication for the future immunization by new tuberculosis subunit vaccines Ag85B-ESAT-6 and Ag85B-TB10.4. J Biomed Biotechnol. 2010;2010:208371. 35. Zvi A, Ariel N, Fulkerson J, Sadoff JC, Shafferman A. Whole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analyses. BMC Med Genomics. 2008;1:18. 36. Aghababa H, Mohabati Mobarez A, Khoramabadi N, Behmanesh M, Mahdavi M, Tebianian M, et al. A comparative approach to strategies for cloning, expression, and purification of Mycobacterium tuberculosis mycolyl transferase 85B and evaluation of immune responses in BALB/c mice. Mol Biotechnol. 2014;56(6):487-97. 37. Smaill F, Xing Z. Human type 5 adenovirus-based tuberculosis vaccine: is the respiratory route of delivery the future? Expert Rev Vaccines. 2014;13(8):927-30. 38. Palma C, Schiavoni G, Abalsamo L, Mattei F, Piccaro G, Sanchez M, et al. Mycobacterium tuberculosis PstS1 amplifies IFN-gamma and induces IL-17/IL-22 responses by unrelated memory CD4+ T cells via dendritic cell activation. Eur J Immunol. 2013;43(9):2386-97. 39. Prugnolle F, Manica A, Charpentier M, Guegan JF, Guernier V, Balloux F. Pathogen-driven selection and worldwide HLA class I diversity. Curr Biol. 2005;15(11):1022-7. 40. Koehler RN, Walsh AM, Sanders-Buell EE, Eller LA, Eller M, Currier JR, et al. High-throughput high-resolution class I HLA genotyping in East Africa. PLoS One. 2010;5(5):e10751. 41. Dunand VA, Ng CM, Wade JA, Bwayo J, Plummer FA, MacDonald KS. HLA-DR 52- and 51-associated DRB1 alleles in Kenya, east Africa. Tissue Antigens. 1997;49(4):397-402. 42. Andersen CS, Dietrich J, Agger EM, Lycke NY, Lovgren K, Andersen P. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect Immun. 2007;75(1):408-16. 43. Blythe MJ, Flower DR. Benchmarking B cell epitope prediction: underperformance of existing methods. Protein Sci. 2005;14(1):246-8. 44. Ponomarenko JV, Bourne PE. Antibody-protein interactions: benchmark datasets and prediction tools evaluation. BMC Struct Biol. 2007;7:64.
45. Ramakrishnan K, Flower DR. Discriminating antigen and non-antigen using proteome